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rheumatoid arthritis treated with abatacept,
rituximab, tocilizumab, or tumour necrosis
factor inhibitors: a prospective cohort study
from southern Sweden
Anders Gülfe1,2*, Johan K. Wallman1,2 and Lars Erik Kristensen3
Abstract
Background: The development of EuroQol-5 dimensions (EQ-5D) utility over time in rheumatoid arthritis (RA) patients,
treated with biologics other than tumour necrosis factor inhibitors (TNFi), based on the standard British (UK) and the
new Swedish (SE) EQ-5D preference sets, has not been previously described.
Methods: Demographics, core set data, EQ-5D utility, and treatment characteristics for patients with established RA,
receiving biologics in southern Sweden from January 2006 to March 2014, were retrieved from observational databases.
Theoretical, UK, and experience-based, SE, EQ-5D mean utilities were plotted over time.
Results: Data regarding 2418 treatment courses with abatacept (ABA, n = 100), rituximab (RTX, n = 230), tocilizumab
(TOC, n = 121), or TNFi (n = 1967) were included in the analysis. Patients starting TNFi treatment, as expected, had
shorter disease duration and less previous biologics. Baseline utilities of patients commencing ABA and TOC, but not
RTX, were also lower than in the TNFi group. Following treatment initiation, rapid utility improvements were seen with
all therapies, reaching plateaus after approximately 1.5 months, and then remaining fairly stable throughout follow-up in
patients adhering to therapy. SE utilities were consistently higher than UK, with baseline values at around 0.7 leaving
little room for improvement.
Conclusions: ABA, RTX, TOC, and TNFi treatments were all associated with favourable EQ-5D utility developments in RA
patients adhering to therapy. The compression of the experience-based SE preference set towards higher utilities may
compromise its ability to detect between-group differences in quality-adjusted life-years, thus making cost-effectiveness
harder to demonstrate in cost-utility analyses applying this preference set, rather than the standard UK.
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Background
Cost-utility analyses (CUA) of novel, costly treatments –
e.g. biologics for rheumatoid arthritis (RA) – are increas-
ingly used to aid resource allocation, and are frequently
referred to by stakeholders, payers, authors of treatment
guidelines and health authorities [1–3]. CUAs are based on
estimates of incremental costs in relation to incremental
accumulation of quality-adjusted life-years (QALYs), typic-
ally comparing a recent intervention to standard treatment
or placebo. QALYs, in turn, are calculated as the area
under the utility curve plotted against time, with utility
being a measure of health-related quality of life (HRQoL),
anchored at 0 (death) and 1 (perfect health). Utility is usu-
ally estimated by means of generic, preference-based
HRQoL instruments, such as the EuroQol-5 dimensions
(EQ-5D) descriptive system, consisting of five questions on
mobility, self-care, usual activities, pain/discomfort and
anxiety/depression, where the respondent is asked to rate
his/her problems at one of three levels (no problem; some
problem; unable to do) [4]. The resulting response consti-
tutes one of 243 possible health states, each of which have
been assigned a specific utility value by means of a valu-
ation process in a reference population. The reference
persons are asked to estimate either their own health
(experience-based valuation) or health states described
to them (hypothetical valuation) by means of a direct
HRQoL instrument, such as time trade-off (TTO),
standard gamble (SG) or visual analogue scale (VAS).
An algorithm, describing the translation of each health
state into a utility value, will then be computed. The
resulting weights (preference set) will thus depend on
the algorithm and on the properties of the reference
population, e.g. demographics, sociocultural factors,
health and a variety of methodological issues, including
the choice between hypothetical or experience-based
valuation [5].
The first and most widely used EQ-5D preference set
was derived by hypothetical valuation in a British (UK)
reference population [6], but there are several other
national preference sets available, based variously on
hypothetical or experience-based, TTO or VAS valua-
tions, each giving rise to different utilities for the same
health states [7, 8]. Whereas the use of such national
preference sets may indeed help reflect the values of the
population in which a CUA is conducted, the variability
of results complicates the comparison of studies. More-
over, national health authorities may express support for
certain methodologies, influencing the development in
their respective countries – the stance of the Swedish
Dental and Pharmaceutical Benefits Agency (Tandvårds-
och Läkemedelsförmånsverket) e.g. being reflected in the
use of experience-based rather than hypothetical valuations
in the creation of the recently published Swedish (SE) EQ-
5D preference set [1, 9].
We have previously demonstrated that EQ-5D utility
gain in tumour necrosis factor inhibitor (TNFi) treat-
ment of established RA is rapid, and that utility remains
stable in those remaining on therapy for up to 7 years
[10]. The development of utility over time in RA pa-
tients treated with other biologics is, however, less well
known. Thus, the present study aims to (i) describe the
utility development during 18 months in established RA
patients starting treatment with abatacept (ABA), rituxi-
mab (RTX), tocilizumab (TOC) or, for comparison, TNFi;
and (ii) to compare the performance of the hypothetical
UK and the experience-based SE EQ-5D preference sets
in this dataset.
Methods
Demographics, core set data, type and date (start; stop) of
treatment and EQ-5D health states at baseline, 2 and
6 weeks, 3, 9, 12 and 18 months were retrieved from
observational databases in southern Sweden for patients
treated with ABA, RTX, TOC, or TNFi in clinical practice.
The study period constituted January 2006 to March
2014. Up to 2012, observational data was routinely
entered into the South Swedish Arthritis Treatment
Group (SSATG) register [11], whereas later the Swedish
Rheumatology Quality Register (SRQ) was used [12].
Diagnoses were as judged by the treating rheumatologists,
which – in a subset of patients – have previously been
demonstrated to agree with the 1987 American College of
Rheumatology (ACR) criteria in 98 % of cases [13, 14].
Mean (95 % CI) EQ-5D utilities for the time points stated
were calculated applying the UK and SE preference sets
and plotted against time. Treatment courses lacking base-
line EQ-5D data were excluded, and individual patients
could contribute data for more than one treatment course
due to switching between therapies. The Kaplan-Meier
method was used to estimate the number of patients
remaining on therapy at each time point. Analysis of co-
variance was used to compare EQ-5D UK/SE utility
change from baseline to 18 months (18-month values im-
puted by last observation carried forward, LOCF) between
the four treatment modalities, adjusting for sex, disease
duration, previous number of biologic treatments, and
baseline EQ-5D utility (according to the respective prefer-
ence sets), health assessment questionnaire (HAQ) and
28-joint disease activity (DAS28) scores. Correlations be-
tween the 18-month changes in EQ-5D UK/SE utility and
HAQ scores (again based on LOCF imputed data) for the
respective therapies were also assessed by Spearman’s rho.
The study was approved by the Regional Ethical
Review Board in Lund, number 2013/208. Oral informed
consent was obtained at first inclusion of data and docu-
mented in the database. Due to the quality control and
safety surveillance character of the registers, no written
consent was required.
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Results
During the study period, 2418 treatment courses of ABA
(n = 100), RTX (n = 230), TOC (n = 121) or TNFi (n =
1967), with EQ-5D data available at baseline, were initi-
ated among 1757 patients. Baseline characteristics of
subjects commencing the various treatments are given
in Table 1. Compared to the other treatments, as ex-
pected, patients initiating TNFi therapy had lower point
estimate means for number of previous biologics, disease
duration, HAQ and DAS28 scores. The point estimate
number of previous biologics was also lower among pa-
tients commencing RTX, as compared to the ABA and
TOC groups.
Mean utility development during 18 months for each
treatment is displayed in Figs. 1, 2, 3 and 4, according to
both UK and SE EQ-5D preference sets. At baseline,
mean (95 % CI) UK utilities were 0.26 (0.19, 0.33), 0.39
(0.34, 0.43), 0.26 (0.20, 0.33) and 0.40 (0.39, 0.42) for pa-
tients starting ABA, RTX, TOC and TNFi, respectively,
while the corresponding SE values were 0.67 (0.64, 0.69),
0.70 (0.69, 0.72), 0.67 (0.64, 0.69) and 0.71 (0.71, 0.72).
Patients commencing ABA or TOC therapy thus started
from lower mean utility levels, whereas the RTX-treated
subjects started from an average utility level similar to
those initiating TNFi. Following treatment initiation,
rapid utility improvements were seen with all therapies,
reaching plateaus after approximately 1.5 months, and
then remaining fairly stable throughout follow-up in pa-
tients adhering to therapy. Numerically, a somewhat
smaller UK utility gain was observed among patients
treated with RTX, as compared to all other treatments.
When adjusting baseline characteristics, however, the
analysis of covariance models did not show any signifi-
cant difference in EQ-5D UK or SE utility change over
18 months between any of the treatment modalities
(p >0.1 for all comparisons).
Improvement in utilities was accompanied by improve-
ment in HAQ disability. Spearman correlation between
EQ-5D UK and HAQ improvements from baseline to
18 months was 0.53, -0.51, -0.59 and -0.48 for ABA, RTX,
TOC and TNFi, respectively. For EQ-5D SE, the corre-
sponding values were -0.52, -0.47, -0.67 and -0.52.
Regarding the choice of EQ-5D preference set, the
experience-based SE utilities were consistently higher
than the hypothetically derived UK, with baseline values
at around 0.7 leaving little room for improvement. Con-
sequently, SE utility gains were numerically much
smaller than UK for all treatments, and potential differ-
ences between the therapies thus less apparent. The
overall patterns of utility development with plateaus
from around 1.5 months, however, remained similar to
the UK findings.
Discussion
Based on observational data from southern Sweden, the
current study demonstrated a rapid improvement of EQ-
5D utility in RA patients commencing treatment with
ABA, RTX, or TOC, and that this improvement was sus-
tained for at least 18 months in patients adhering to
therapy. Data for patients initiating TNFi treatment is
also provided for comparison.
Compared to patients starting TNFi or RTX, the lower
mean baseline utilities of the ABA and TOC groups are
likely explained by more treatment-refractory disease, as
signalled by their higher mean numbers of previous bio-
logics. Mean DAS28 and HAQ scores, both known to
correlate with EQ-5D utility [15, 16], were also numeric-
ally worse in these groups at treatment initiation. In view
of the baseline characteristics, the finding that patients
commencing RTX had mean baseline utility on par with
the TNFi group was, however, more unexpected, and
reasons for this remain partly unresolved.
The pattern of relative stability of utilities in patients
remaining on therapy, once treatment response had been
achieved, was similar for all treatment modalities, and is
Table 1 Baseline characteristics by therapy
Abatacept Rituximab Tocilizumab TNFi
N 100 230 121 1967
Age, years 59.0 (12.1) 60.2 (12.3) 57.9 (13.5) 56.6 (13.6)
Female, n (%) 82 (80.4) 166 (72.2) 98 (80.3) 1520 (77.3)
Disease duration, years 14.1 (9.6) 15.6 (11.0) 14.1 (9.6) 11.6 (10.8)
Baseline HAQ 1.46 (0.61) 1.35 (0.67) 1.43 (0.64) 1.18 (0.64)
Baseline DAS28 5.81 (1.30) 5.30 (1.48) 5.71 (1.32) 5.09 (1.32)
Number of previous biologic courses 2.5 (1.5) 1.8 (1.4) 2.3 (1.4) 0.6 (1.0)
Number of ongoing DMARDsa 0.7 (1.0) 0.8 (0.6) 0.7 (0.6) 0.9 (0.6)
Ongoing steroids, yes, n (%) 66 (64.7) 156 (67.8) 82 (67.2) 1164 (59.2)
Values are mean (SD) unless stated otherwise
TNFi tumour necrosis factor inhibitors, HAQ health assessment questionnaire, DAS28 28-joint disease activity score, DMARD disease-modifying anti-rheumatic drug
aExcluding ongoing biologics
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well in line with previous findings limited to TNFi
therapy [10].
Due to the observational setting, with patient groups
not being entirely comparable, the numerically lower UK
utility gain in the RTX group should be interpreted with
caution, and did not differ significantly from those of the
other treatments after adjustment for baseline differ-
ences. Despite starting from similar mean utility levels,
in relation to the TNFi group, the average RTX patient
had indeed more long-standing and treatment-refractory
disease (Table 1). On the opposite side, the numerically
larger mean UK utility gains of the ABA/TOC groups
Fig. 1 EuroQoL-5 dimensions utility development according to British (UK) and Swedish (SE) preference sets in established rheumatoid arthritis
treated with abatacept
Fig. 2 EuroQoL-5 dimensions utility development according to British (UK) and Swedish (SE) preference sets in established rheumatoid arthritis
treated with rituximab
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may at least partly be driven by instrument effects, since
when starting from gradually worse EQ-5D health states,
ever smaller improvements of the questionnaire responses
are required to achieve the same UK utility gain [17]. For
comparison, in terms of HAQ developments (data not
shown), the RTX group more closely resembled those of
patients commencing ABA or TOC than TNFi. Finally, in
randomized controlled trials, the efficacy of all the studied
treatment modalities has been found to be of similar
magnitude [18, 19].
Another main point of interest of the current study is the
substantial difference observed between the hypothetical
Fig. 3 EuroQoL-5 dimensions utility development according to British (UK) and Swedish (SE) preference sets in established rheumatoid arthritis
treated with tocilizumab
Fig. 4 EuroQoL-5 dimensions utility development according to British (UK) and Swedish (SE) preference sets in established rheumatoid arthritis
treated with tumour necrosis factor inhibitors
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UK and the experience-based SE utilities, derived from the
same EQ-5D questionnaire answers. Even though some
gain in SE utility occurred over time, the compression of
the SE preference set – with the worst possible health state,
33333, corresponding to a utility score of 0.34, as compared
to -0.59 by use of the UK weights – clearly constrains the
magnitude of potential improvement. Differences in QALY
accumulation between interventions with varying efficacy
may thus also be lower when applying the SE, as opposed
to the UK, preference set, potentially affecting the conclu-
sion of CUAs. While disparities also exist between different
hypothetical EQ-5D preference sets [8], experience-based
valuations are known to result in higher utilities [9], and
likely explain the pronounced differences observed between
the UK and SE results.
As has already been alluded to, the open, non-
randomized nature of observational studies generates
methodological limitations. Confounding by indication
as well as assessment and performance bias cannot be
excluded from this study. Any direct head-to-head drug
interpretations should thus be done with care, and need
to be confirmed in other studies and different settings.
Moreover, we chose to group all anti-TNF remedies to-
gether, rather than to perform separate analyses for the
various agents. Another limitation is, EQ-5D data was
only available from patients remaining on therapy and
the presented figures are based on observed data only,
thus introducing attrition bias. Rather than describing
mean utility developments of all patients starting the
various treatments, the current data should be inter-
preted as reflecting the situation in those adhering to
therapy. On the other hand, by only including unim-
puted data in the figures, they describe what has actually
been observed in the study population.
Conclusions
The present study showed rapid and sustained EQ-5D
utility improvements in RA patients commencing and
adhering to treatment with ABA, RTX, TOC and TNFi.
Moreover, large differences were observed between EQ-
5D utilities derived by use of the hypothetical UK or the
experience-based SE preference sets, underscoring the
important impact the choice of EQ-5D preference set
may have on the outcome and interpretation of CUAs
applying this instrument.
Abbreviations
ABA: Abatacept; ACR: American College of Rheumatology; CUA: Cost-utility
analysis; DAS28: 28-Joint disease activity score; EQ-5D: EuroQoL-5 dimensions;
HAQ: Health assessment questionnaire; HRQoL: Health-related quality of life;
QALY: Quality-adjusted life-years; RA: Rheumatoid arthritis; RTX: Rituximab;
SE: Swedish; SG: Standard gamble; SRQ: Swedish Rheumatology Quality
Register; SSATG: South Sweden Arthritis Treatment Group; TNFi: Tumour
necrosis factor inhibitor; TOC: Tocilizumab; TTO: Time trade-off; UK: British;
VAS: Visual analogue scale.
Competing interests
AG has no competing interests. JKW has participated in an advisory board
for Novartis, unrelated to the current work. LEK has received fees for speaking
and consultancy from Pfizer, UCB, Roche, BMS, Abbvie and MSD.
Authors’ contributions
AG conceived the study, drafted the manuscript, compiled and analysed the
data and is guarantor for the integrity of data. JKW handled the databases,
analysed data and helped draft the manuscript. LEK analysed data and helped
draft the manuscript. All authors read and approved the final manuscript.
Acknowledgements
We are indebted to all colleagues and staff in the South Swedish Arthritis
Treatment Group for cooperation and data supply, to Ms Minna Willim for
help with databases and to Ms Sofie Eklund for preparation of the figures.
Funding
This study was supported by grants from the Österlund and Kock Foundations,
King Gustav V’s 80-year Fund, Lund University Hospital Funds, and Reumatiker-
förbundet. LEK is sponsored by the Oak Foundation.
Author details
1Department of Clinical Sciences Lund, Rheumatology Section, Lund
University, 221 84 Lund, Sweden. 2Department of Rheumatology, Skåne
University Hospital, 221 85 Lund, Sweden. 3The Parker Institute, Department
of Rheumatology, Copenhagen University Hospital, Bispebjerg and
Frederiksberg, 2000 Copenhagen, Denmark.
Received: 5 October 2015 Accepted: 8 February 2016
References
1. Tandvårds- och Läkemedelsförmånsverket. http://www.tlv.se. Accessed 6
July 2015.
2. National Institute for Health and Care Excellence. http://www.nice.org.uk.
Accessed 6 July 2015.
3. Svensk Reumatologisk Förening. http://www.svenskreumatologi.se. Accessed
6 July 2015.
4. The EuroQol Group. EuroQoL - a new facility for the measurement of
health-related quality of life. Health Policy. 1990;16:199–208.
5. Harrison MJ, Bansback NJ, Marra CA, Drummond M, Tugwell PS, Boonen A.
Valuing health for clinical and economic decisions: directions relevant for
rheumatologists. J Rheumatol. 2011;38:1770–5.
6. Harrison MJ, Davies LM, Bansback NJ, Ingram M, Anis AH, Symmons DP. The
validity and responsiveness of generic utility measures in rheumatoid
arthritis: a review. J Rheumatol. 2008;35:592–602.
7. Nan L, Johnson JA, Shaw JW, Coons SJ. A comparison of EQ-5D index
scores derived from the US and UK population-based scoring functions.
Med Decis Making. 2007;27:321–6.
8. Karlsson JA, Nilsson JA, Neovius M, Kristensen LE, Gulfe A, Saxne T, et al.
National EQ-5D tariffs and quality-adjusted life-year estimation: comparison
of UK, US and Danish utilities in south Swedish rheumatoid arthritis
patients. Ann Rheum Dis. 2011;70:2163–6.
9. Burstrom K, Sun S, Gerdtham UG, Henriksson M, Johannesson M, Levin LA,
et al. Swedish experience-based value sets for EQ-5D health states. Qual Life
Res. 2014;23:431–42.
10. Gulfe A, Kristensen LE, Saxne T, Jacobsson LT, Petersson IF, Geborek P. Rapid
and sustained health utility gain in anti-tumour necrosis factor-treated
inflammatory arthritis: observational data during 7 years in southern
Sweden. Ann Rheum Dis. 2010;69:352–7.
11. Geborek P, Saxne T. Clinical protocol for monitoring of targeted therapies in
rheumatoid arthritis. Rheumatology (Oxford). 2000;39:1159–61.
12. Svensk Reumatologis Kvalitetsregister. http://www.srq.nu. Accessed 6 July 2015.
13. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al.
The American Rheumatism Association 1987 revised criteria for the
classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315–24.
14. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and
leflunomide in established rheumatoid arthritis: clinical experience using a
structured follow up programme in southern Sweden. Ann Rheum Dis.
2002;61:793–8.
Gülfe et al. Arthritis Research & Therapy  (2016) 18:51 Page 6 of 7
15. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related
quality of life in rheumatoid arthritis: validity, responsiveness and reliability
of EuroQol (EQ-5D). Br J Rheumatol. 1997;36:551–9.
16. Radner H, Smolen JS, Aletaha D. Remission in rheumatoid arthritis: benefit
over low disease activity in patient reported outcomes and costs. Arthritis
Res Ther. 2014;16:R56.
17. Dolan P. Modeling valuations for EuroQol health states. Med Care. 1997;35:
1095–108.
18. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsoe B,
Saxne T. The number needed to treat for adalimumab, etanercept, and
infliximab based on ACR50 response in three randomized controlled trials
on established rheumatoid arthritis: a systematic literature review. Scand J
Rheumatol. 2007;36:411–7.
19. Kristensen LE, Jakobsen AK, Bartels EM, Geborek P, Bliddal H, Saxne T, et al.
The number needed to treat for second-generation biologics when treating
established rheumatoid arthritis: a systematic quantitative review of
randomized controlled trials. Scand J Rheumatol. 2011;40:1–7.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Gülfe et al. Arthritis Research & Therapy  (2016) 18:51 Page 7 of 7
